High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis

Read full text
Authors: Yun Chiang, Yu-Chieh Tsai, Chung-Chieh Wang, Fu-Jen Hsueh, Chaoyuan Huang, Chung-Hsin Chen, Yeong-Shiau Pu, Shih-Chieh Jeff Chueh, Xavier Cheng-Hong Tsai, Jason Chia‐Hsien Cheng
Cited by: 2
References: 53

Abstract

BACKGROUND: Radiation (RT)-promoted distant metastasis (DM) is an underrecognized complication that can compromise the therapeutic efficacy of local RT. This study aimed to identify tumor microenvironment (TME) traits that predispose to RT-promoted DM and provide mechanistic insights for potential therapeutic intervention. METHODS: We performed NanoString analysis on tumor samples from urothelial cancer patients to compare the TME profiles of those with and without RT-promoted DM. To complement clinical findings, we conducted RNA sequencing (RNAseq) of murine bladder cancer cell lines, MB49 (with RT-promoted DM) and MBT2 (without), followed by in vivo ectopic tumor modeling, flow cytometry of immune cell infiltrates, and cytokine array profiling. RESULTS: NanoString analysis revealed a significant enrichment of C-X-C motif receptor 2 (CXCR2)-expressing neutrophils in the TME of patients with RT-promoted DM. These tumors also exhibited nuclear factor kappa B (NFκB) activation and increased secretion of neutrophil-recruiting chemokines. RNAseq and cytokine profiling identified CD14 expression in tumor cells as a key upstream regulator of neutrophilic TME via NFκB signaling. The use of antagonists to block neutrophils and inhibit CD14 expression in cancer cells, which reduces the secretion of neutrophil-recruiting chemokines, effectively mitigated RT-promoted DM in both the MB49 and LLC mouse models. CONCLUSIONS: CD14 expression in tumor cells plays a pivotal role in shaping a neutrophil-enriched TME, which increases the susceptibility to RT-promoted DM. CD14 represents a potential predictive biomarker and therapeutic target for mitigating this adverse outcome.

Fields of Study & Subjects

Immune cells in cancer Chemokine receptors and signaling Cancer Research and Treatments

Publication details

Journal / source
Journal of Biomedical Science
Publisher
Springer Science and Business Media LLC
Volume
33
Issue
1
Pages
2–2
Publication date
4 January 2026
Language
EN